Screener
Dyne Therapeutics, Inc. DYN Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Dyne Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 7:25 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-215702
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $753,102 | $893,369 |
| Marketable securities | 219,054 | 217,193 |
| Prepaid expenses and other current assets | 48,871 | 16,025 |
| Total current assets | 1,021,027 | 1,126,587 |
| Property and equipment, net | 23,682 | 24,029 |
| Right-of-use assets | 19,652 | 20,742 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dyne Therapeutics, Inc.'s cash & equivalents?
- Dyne Therapeutics, Inc. (DYN) reported cash & equivalents of $753.1M in Q1 2026.
- How has Dyne Therapeutics, Inc.'s cash & equivalents changed year-over-year?
- Dyne Therapeutics, Inc.'s cash & equivalents increased by 59.5% year-over-year, from $472.26M to $753.1M.
- What is the long-term trend for Dyne Therapeutics, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Dyne Therapeutics, Inc.'s cash & equivalents has grown at a 24.3% compound annual growth rate (CAGR), from $300.85M to $893.37M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Dyne Therapeutics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude